193009-11-9

Upstream product

• 160891-99-6 N-[3-(6-methoxy-2-methyl-4-oxo-4H-chromen-3-yl methyl)phenyl]acetamide 
• 193009-09-5 3-(3-Amino-benzyl)-6-methoxy-2-methyl-chromen-4-one 
• 193009-10-8 C,C,C-Trifluoro-N-[3-(6-methoxy-2-methyl-4-oxo-4H-chromen-3-ylmethyl)phenyl]methanesulfonamide 

Downstream Products

• 193009-12-0 C,C,C-Trifluoro-N-{3-[6-(5-fluorobenzothiazol-2-ylmethoxy)-2-methyl-4-oxo-4H-chromen-3-ylmethyl]phenyl}methanesulfonamide 

Relevant academic research and scientific papers

Development of new chromanol antagonists of leukotriene D4

By addressing the issues of potency and metabolism in 3, a new series of LTD4 antagonists represented by (+)-26 was developed which is equipotent to clinical LTD4 antagonists Zafirlukast (1) and Pranlukast (2).

SULFONAMIDE DERIVATIVES OF BENZENEFUSED HYDROXY SUBSTITUTED CYCLOALKYL AND HETEROCYCLIC RING COMPOUNDS

Compounds of the formula STR1 and pharmaceutically acceptable salts and prodrugs thereof, wherein X 1, Ar, X, Y 1, R. sup.1, R. sup.2, R 3, R 5 and n are defined below, which are inhibitors of the production of leukotrienes and/or blockers of leukotriene